Key result
In atrial fibrillation patients on vitamin K antagonists, median major bleeding incidence was similar between RCTs (2.1 per 100 patient-years) and observational studies (2.0 per 100 patient-years).
Why the study?
What is the incidence of major bleeding and mortality in patients with atrial fibrillation treated with vitamin K antagonists?
Population
Patients with atrial fibrillation from 47 studies with cumulative follow-up of 61,563 patient-years for RCTs…
Design
Systematic_review
Authors
Loading...
Supports incorporating observational data into bleeding risk estimates for AF on VKAs; confirms alignment with RCT findings.
Systematic Review
What is the incidence of major bleeding and mortality in patients with atrial fibrillation treated with vitamin K antagonists?
Absolute Event Rate: 2.1% vs 2%
The median rate of major bleeding in patients with atrial fibrillation treated with vitamin K antagonists is similar between RCTs and observational studies, though real-world data shows greater heterogeneity.
Roskell et al. (2013) conducted a systematic review in Atrial fibrillation. Vitamin K antagonists was evaluated on Major bleeding. In atrial fibrillation patients on vitamin K antagonists, median major bleeding incidence was similar between RCTs (2.1 per 100 patient-years) and observational studies (2.0 per 100 patient-years).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: